Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, ...

month data show patients with generalized myasthenia gravis taking efgartigimod were able to reduce glucocorticoids to low levels or discontinue them.

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...

1. Willi R, Bril V, Howard J, et al. RELIEVE: a phase 3 study evaluating the efficacy and safety of remibrutinb in generalized myasthenia gravis. Presented at: American Association of Neuromuscular & ...

Beyond the 4-week mark, both MG-ADL and Quantitative Myasthenia Gravis scores improved in the overall population and in all ...

What are called autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most ...

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...